Literature DB >> 20462780

Early-onset progressive osteoarthritis with hereditary progressive ophtalmopathy or Stickler syndrome.

Tifenn Couchouron1, Charles Masson.   

Abstract

Stickler syndrome is a group of rare genetic conditions (incidence, 1/7500 births) related to mutations in the collagen genes. Both the mutations and the clinical features vary widely across affected patients. The main manifestations are craniofacial birth defects, bone and joint symptoms, ocular abnormalities, and hearing loss. Stickler syndrome may be revealed at birth (25% of cases) by a combination of cleft palate, retrognathism, and micrognathism known as Pierre Robin sequence, which may cause neonatal respiratory problems. The ocular abnormalities include severe myopia, abnormalities of the vitreous, and a high risk of retinal detachment (60% of cases), which may cause blindness (4% of cases). Severe hearing loss with onset in early childhood may impair performance at school. Osteoarthritis (75% of patients) with onset before 30 years of age is a severe manifestation that causes chronic hip and low back pain and functional impairments. Joint replacement surgery is often required. The risk associated with multiple anesthesias is highest in patients with craniofacial defects. The bone status may deserve to be evaluated, as the combination of genetic abnormalities and physical impairments may promote bone loss. Clinicians should be cognizant of Stickler syndrome so that they can detect the disease in patients and their family members, prevent functional impairments, organize a multidisciplinary management strategy, and arrange for genetic counseling. Copyright Â
© 2010 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20462780     DOI: 10.1016/j.jbspin.2010.03.012

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  7 in total

1.  Stickler syndrome associated with epilepsy: report of three cases.

Authors:  Salvatore Savasta; Vincenzo Salpietro; Maria Valentina Spartà; Thomas Foiadelli; Daniela Laino; Lucio Lobefalo; Gian Luigi Marseglia; Alberto Verrotti
Journal:  Eur J Pediatr       Date:  2015-03-27       Impact factor: 3.183

Review 2.  [Hereditary hearing loss: Part 2: Syndromic forms of hearing loss].

Authors:  W F Burke; T Lenarz; H Maier
Journal:  HNO       Date:  2014-10       Impact factor: 1.284

3.  Osteoarthritis at young age, a diagnostic challenge: a case of stickler syndrome.

Authors:  Isabelle de Wergifosse; Rene Westhovens
Journal:  Open Rheumatol J       Date:  2014-12-19

Review 4.  Endoplasmic Reticulum Stress and Unfolded Protein Response in Cartilage Pathophysiology; Contributing Factors to Apoptosis and Osteoarthritis.

Authors:  Alexandria Hughes; Alexandra E Oxford; Ken Tawara; Cheryl L Jorcyk; Julia Thom Oxford
Journal:  Int J Mol Sci       Date:  2017-03-20       Impact factor: 5.923

5.  Variable clinical expression of Stickler Syndrome: A case report of a novel COL11A1 mutation.

Authors:  Evelise Brizola; Maria Gnoli; Morena Tremosini; Paolo Nucci; Sara Bargiacchi; Andrea La Barbera; Sabrina Giglio; Luca Sangiorgi
Journal:  Mol Genet Genomic Med       Date:  2020-06-17       Impact factor: 2.183

6.  The mechanical impact of col11a2 loss on joints; col11a2 mutant zebrafish show changes to joint development and function, which leads to early-onset osteoarthritis.

Authors:  Elizabeth A Lawrence; Erika Kague; Jessye A Aggleton; Robert L Harniman; Karen A Roddy; Chrissy L Hammond
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-09-24       Impact factor: 6.237

7.  Regenerating zebrafish scales express a subset of evolutionary conserved genes involved in human skeletal disease.

Authors:  John P Kemp; Chrissy L Hammond; Juriaan R Metz; Dylan J M Bergen; Qiao Tong; Ankit Shukla; Elis Newham; Jan Zethof; Mischa Lundberg; Rebecca Ryan; Scott E Youlten; Monika Frysz; Peter I Croucher; Gert Flik; Rebecca J Richardson
Journal:  BMC Biol       Date:  2022-01-21       Impact factor: 7.431

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.